The invention relates to novel organic semiconducting compounds containing a polycyclic unit, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to the use of the compounds, compositions and polymer blends as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, perovskite-based solar cell (PSC) devices, organic photodetectors (OPD), organic field effect transistors (OFET) and organic light emitting diodes (OLED), and to OE, OPV, PSC, OPD, OFET and OLED devices comprising these compounds, compositions or polymer blends.

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

The present application relates to a compound of a formula (I), to the use thereof in electronic devices, to processes for preparing the compound, and electronic devices comprising the compound.

The present application relates to a compound of a formula (I), to the use thereof in electronic devices, to processes for preparing the compound, and electronic devices comprising the compound.

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

A novel organic compound that is effective in improving the element characteristics and reliability is provided. The organic compound, which is represented by General Formula (G1), has a structure in which a dibenzoquinazoline ring is bonded to a skeleton with a hole-transport property via one or more arylene groups.

##STR00001##

Any one of R.sup.1 to R.sup.9 in General Formula (G1) is bonded to any one of R.sup.10 to R.sup.14 in General Formula (G1-1). Note that n is any of 0 to 3; m is 1 or 2; A represents a single bond, or an arylene group; B represents a ring having a dibenzofuran skeleton, dibenzothiophene skeleton, or carbazole skeleton; and each of R.sup.1 to R.sup.15 independently represents any of hydrogen, an alkyl group, a cycloalkyl group, and an aryl group.

A novel organic compound that is effective in improving the element characteristics and reliability is provided. The organic compound, which is represented by General Formula (G1), has a structure in which a dibenzoquinazoline ring is bonded to a skeleton with a hole-transport property via one or more arylene groups.

##STR00001##

Any one of R.sup.1 to R.sup.9 in General Formula (G1) is bonded to any one of R.sup.10 to R.sup.14 in General Formula (G1-1). Note that n is any of 0 to 3; m is 1 or 2; A represents a single bond, or an arylene group; B represents a ring having a dibenzofuran skeleton, dibenzothiophene skeleton, or carbazole skeleton; and each of R.sup.1 to R.sup.15 independently represents any of hydrogen, an alkyl group, a cycloalkyl group, and an aryl group.

A compound having a metal coordination complex structure, where the compound is capable of functioning as a phosphorescent emitter in an organic light emitting device at room temperature is disclosed. The compound has a first ligand coordinated to a metal. The free-state of the first ligand has a first triplet energy T1 of E.sub.L at 77K, while the compound has a first triplet energy T1 of E at 77K, and the difference in energy (ΔE) between E and E.sub.L is ≤250 meV. The compound has a triplet emission spectrum with a FWHM value of no more than 45 nm. Organic light emitting devices, consumer products, and formulations containing the compounds are also disclosed.